📰 Objective Response Rate News
Page 4 - Objective Response Rate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Objective Response Rate. Real-time updates on events, politics, business and more.
October 26, 2023
Shay Elkins, a patient with metastatic triple-negative breast cancer, discussed her experience with second-line treatment. Dr. Noor provided insights into the positive outcomes from the ASCENT study.
October 12, 2023
Tempest Therapeutics (NASDAQ: TPST) experienced a remarkable market upswing of over 2,800%, showcasing one of the most substantial gains this year for a once tiny biotech company trading on the Nasdaq. The surge is undeniably tied to their recent press release. However, decoding the significance of this update can be puzzling for everyday investors who
September 6, 2023
/PRNewswire/ -- Guangzhou Gloria Biosciences ("GloriaBio"), a commercial stage biopharmaceutical company focusing on the discovery, development and...
July 6, 2023
Randomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination...
June 9, 2023
-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- -- WU-CART-007 demonstrated preliminary evidence of anti-leukemic
June 5, 2023
/PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical...
June 5, 2023
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter's Transformation (RT), responded to treatment (Objective Response Rate of 100%)1
June 5, 2023
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on...
June 5, 2023
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia , with or without Richter’s Transformation , responded to treatment 1 GLPG5201 showed no cytokine... | June 5, 2023
June 3, 2023
Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate